Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript

Core Viewpoint - Pyxis Oncology is conducting a clinical update call regarding its MICVO treatment for recurrent metastatic head and neck squamous cell carcinoma, indicating ongoing developments in its clinical research efforts [2]. Group 1: Company Overview - Alex Kane serves as the Senior Vice President of Investor Relations and Capital Markets at Pyxis Oncology, leading the discussion on the clinical update [2]. - The call will feature remarks from Lara Sullivan, the President, CEO, and CMO of Pyxis Oncology, followed by a Q&A session with her and other team members [2]. Group 2: Clinical Update - The focus of the call is on the clinical update for MICVO, specifically targeting recurrent metastatic head and neck squamous cell carcinoma, highlighting the company's commitment to advancing its oncology pipeline [2].